

DAFTAR PUSTAKA

1. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pengendalian Tuberkulosis 2014. Kementerian Kesehatan Republik Indonesia. 2014;
2. WHO. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020. WHO Publication. 2020.
3. Perhimpunan Dokter Paru Indonesia; 2021.Tuberkulosis, Pedoman Diagnosis dan penatalaksanaan di Indonesia. 2021
4. Airlangga University Press. Manajemen Tuberkulosis, Terkini, Multidisplin dan Komprehensif. 2021
5. Clifford V, Zufferey C, Street A, Denholm J, Tebruegge M, Curtis N. Cytokines for monitoring anti-tuberculous therapy: A systematic review. *Tuberculosis*. 2015.
6. Ei O, II O, Hu N, Dc N. iMedPub Journals Evaluation of Interferon-Gamma , Interleukin 6 and Interleukin 10 in Tuberculosis Patients in Umuahia Methods of Sample Analysis. 2019;1–6.
7. Seyedhosseini FS, Mohammadi S, Ebrahimabad MZ, Khodabakhshi B, Abbasi A, Yazdani Y. Interleukin-6, interleukin-17 and transforming growth factor-beta are overexpressed in newly diagnosed tuberculosis patients; potent biomarkers of mycobacterial infection. *Arch Clin Infect Dis*. 2019;
8. Wahyu Setiani Wibowo. Perbedaan Kadar Interleukin-6 dan Tumor Necrosis Factor Plasma Orang Sehat, Penderita Tuberkulosis Paru. Departemen Patologi Klinik. Universitas Airlangga. 2017.
9. Riskesdas. Kemenkes RI. Profil Kesehatan Indonesia 2019. Data dan Informasi. Kementerian Kesehatan RI; 2019. Jurnal Ilmu Kesehatan. 2019.
10. Shahverdi E, Ma K. Epidemiology of Pulmonary Tuberculosis. *Austin Tuberc Res Treat*. 2018;2(June):1–2.
11. Aru W. Sudoyo. dkk. Buku Ajar Ilmu Penyakit Dalam Jilid III Edisi VI. Ilmu Penyakit Dalam. 2014.
12. Chai Q, Zhang Y, Liu CH. Mycobacterium tuberculosis: An adaptable pathogen associated with multiple human diseases. *Frontiers in Cellular and Infection Microbiology*. 2018.
13. Abrahams KA, Besra GS. Mycobacterial cell wall biosynthesis: A multifaceted antibiotic target. *Parasitology*. 2018.
14. Kalscheuer R, Palacios A, Anso I, Cifuentes J, Anguita J, Jacobs WR, et al. The Mycobacterium tuberculosis capsule: A cell structure with key implications in pathogenesis. *Biochemical Journal*. 2019.

15. Raffetseder J. Interplay of human macrophages and *Mycobacterium tuberculosis* phenotypes. Linköping University Electronic Press. 2016.
16. Zhang C-Y, Zhao F, Xia Y-Y, Yu Y-L, Shen X, Lu W, et al. Prevalence and risk factors of active pulmonary tuberculosis among elderly people in China: a population based cross-sectional study. *Infect Dis Poverty*. 2019;
17. Snow KJ, Sismanidis C, Denholm J, Sawyer SM, Graham SM. The incidence of tuberculosis among adolescents and young adults: A global estimate. *Eur Respir J*. 2018;
18. Horton KC, MacPherson P, Houben RMGJ, White RG, Corbett EL. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. *PLoS Medicine*. 2016.
19. World Health Organization (WHO). HIV-Associated Tuberculosis. factsheet. 2018.
20. Ahmed A, Rakshit S, Vyakarnam A. HIV-TB co-infection: Mechanisms that drive reactivation of *Mycobacterium tuberculosis* in HIV infection. *Oral Dis*. 2016;
21. Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and mycobacterium tuberculosis co-infection. *Nature Reviews Microbiology*. 2018.
22. Feleke BE, Feleke TE, Biadglegne F. Nutritional status of tuberculosis patients, a comparative cross-sectional study. *BMC Pulm Med*. 2019;
23. Kim SJ, Ye S, Ha E, Chun EM. Association of body mass index with incident tuberculosis in Korea. *PLoS One*. 2018;
24. Sinha P, Davis J, Saag L, Wanke C, Salgame P, Mesick J, et al. Undernutrition and Tuberculosis: Public Health Implications. *Journal of Infectious Diseases*. 2019.
25. Amere GA, Nayak P, Salindri AD, Narayan KMV, Magee MJ. Contribution of smoking to tuberculosis incidence and mortality in high-tuberculosis-burden countries. *Am J Epidemiol*. 2018;
26. Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, et al. Risk factors for tuberculosis: Diabetes, smoking, alcohol use, and the use of other drugs. *Jornal Brasileiro de Pneumologia*. 2018.
27. Loddenkemper R, Brönnecke M, Castell S, Diel R. Tuberculosis and Tobacco Smoking. *Pneumologie*. 2016;70(1):17–22.
28. Solá E, Rivera C, Mangual M, Martinez J, Rivera K, Fernandez R. Diabetes mellitus: An important risk factor for reactivation of tuberculosis. *Endocrinol Diabetes Metab Case Reports*. 2016;
29. Wagnew F, Eshetie S, Alebel A, Dessie G, Tesema C, Abajobir AA. Meta-analysis of the prevalence of tuberculosis in diabetic patients and

- its association with cigarette smoking in African and Asian countries. *BMC Res Notes.* 2018;
30. Zheng C, Hu M, Gao F. Diabetes and pulmonary tuberculosis: a global overview with special focus on the situation in Asian countries with high TB-DM burden. *Glob Health Action.* 2017;
31. Imtiaz S, Shield KD, Roerecke M, Samokhvalov A V., Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: Meta-analyses and burden of disease. *Eur Respir J.* 2017;
32. Myers B, Bouton TC, Ragan EJ, White LF, McIllemon H, Theron D, et al. Impact of alcohol consumption on tuberculosis treatment outcomes: A prospective longitudinal cohort study protocol. *BMC Infect Dis.* 2018;
33. Arroyo-Onnelas M, Concepcin M, V. H, M. V, M. L. Immune Diagnosis of Tuberculosis Through Novel Technologies. In: *Understanding Tuberculosis - Global Experiences and Innovative Approaches to the Diagnosis.* 2012.
34. Yuk JM, and Jo EK. 2014. Host Immune Responses to Mycobacterial Antigens and Their Implications for the Development of a Vaccine to Control Tuberculosis, 3(2):155.
35. Churchyard G, Kim P, Shah NS, Rustomjee R, Gandhi N, Mathema B, et al. What We Know about Tuberculosis Transmission: An Overview. *Journal of Infectious Diseases.* 2017.
36. Turner RD, Bothamley GH. Cough and the transmission of tuberculosis. *Journal of Infectious Diseases.* 2015.
37. Patterson B, Wood R. Is cough really necessary for TB transmission? *Tuberculosis.* 2019.
38. Tellier R, Li Y, Cowling BJ, Tang JW. Recognition of aerosol transmission of infectious agents: A commentary. *BMC Infectious Diseases.* 2019.
39. Turner RD, Chiu C, Churchyard GJ, Esmail H, Lewinsohn DM, Gandhi NR, et al. Tuberculosis Infectiousness and Host Susceptibility. *J Infect Dis.* 2017;
40. Acuña-Villaorduña C, White LF, Fnelly KP, Jones-López EC. Tuberculosis transmission: Sputum vs aerosols. *The Lancet Infectious Diseases.* 2016.
41. CDC. Module 1 - Transmission and pathogenesis of tuberculosis. Self-Study Modul Tuberc. 2019;(1):1–31.
42. Hsia CCW, Hyde DM, Weibel ER. Lung structure and the intrinsic challenges of gas exchange. *Compr Physiol.* 2016;
43. Principi N, Esposito S. Nasal irrigation: An imprecisely defined medical procedure. *International Journal of Environmental Research and Public Health.* 2017.

44. Torrelles JB, Schlesinger LS. Integrating Lung Physiology, Immunology, and Tuberculosis. *Trends in Microbiology*. 2017.
45. Rokicki W, Rokicki M, Wojtacha J, Dzeljilji A. The role and importance of club cells (Clara cells) in the pathogenesis of some respiratory diseases. *Kardiochirurgia i Torakochirurgia Pol.* 2016;
46. Whitsett JA. Airway epithelial differentiation and mucociliary clearance. In: *Annals of the American Thoracic Society*. 2018.
47. Arcos J, Sasindran SJ, Moliva JI, Scordo JM, Sidiki S, Guo H, et al. Mycobacterium tuberculosis cell wall released fragments by the action of the human lung mucosa modulate macrophages to control infection in an IL-10-dependent manner. *Mucosal Immunol.* 2017;
48. Thacker V V, Dhar N, Sharma K, Barrile R, Karalis K, Mckinney JD. A lung-on-chip infection model reveals protective and permissive roles of alveolar epithelial cells in tuberculosis. *bioRxiv*. 2020;
49. Queval CJ, Brosch R, Simeone R. The macrophage: A disputed fortress in the battle against Mycobacterium tuberculosis. *Frontiers in Microbiology*. 2017.
50. Uribe-Quero E, Rosales C. Control of phagocytosis by microbial pathogens. *Frontiers in Immunology*. 2017.
51. Kumar R, Singh P, Kolloli A, Shi L, Bushkin Y, Tyagi S, et al. Immunometabolism of Phagocytes During Mycobacterium tuberculosis Infection. *Frontiers in Molecular Biosciences*. 2019.
52. Pahari S, Kaur G, Aqdas M, Negi S, Chatterjee D, Bashir H, et al. Bolstering immunity through pattern recognition receptors: A unique approach to control tuberculosis. *Frontiers in Immunology*. 2017.
53. Khan N, Vidyarthi A, Pahari S, Negi S, Aqdas M, Nadeem S, et al. Signaling through NOD-2 and TLR-4 Bolsters the T cell Priming Capability of Dendritic cells by Inducing Autophagy. *Sci Rep.* 2016;
54. Romero MM, Basile JI, Corra Feo L, López B, Ritacco V, Alemán M. Reactive oxygen species production by human dendritic cells involves TLR2 and dectin-1 and is essential for efficient immune response against Mycobacteria. *Cell Microbiol.* 2016;
55. Bussi C, Gutierrez MG. Mycobacterium tuberculosis infection of host cells in space and time. *FEMS Microbiology Reviews*. 2019.
56. Vickers CF, Silva APG, Chakraborty A, Fernandez P, Kurepina N, Saville C, et al. Structure-Based Design of MptpB Inhibitors That Reduce Multidrug-Resistant Mycobacterium tuberculosis Survival and Infection Burden in Vivo. *J Med Chem.* 2018;
57. Mori M, Mode R, Pieters J. From phagocytes to immune defense: Roles for coronin proteins in dictyostelium and mammalian immunity. *Frontiers in Cellular and Infection Microbiology*. 2018.

58. Yeldu MH, Ibrahim Y, Akuyam SA, Danasabe IM, Shehu B, Danjuma M, et al. Oxidative stress biomarkers in pulmonary tuberculosis patients in Gombe, North-eastern Nigeria. *Asian J Med Sci.* 2019;
59. Zhai W, Wu F, Zhang Y, Fu Y, Liu Z. The immune escape mechanisms of *Mycobacterium Tuberculosis*. *International Journal of Molecular Sciences.* 2019.
60. Dan Dunn J, Alvarez LAJ, Zhang X, Soldati T. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. *Redox Biology.* 2015.
61. Garcia-Aguilar T, Espinosa-Cueto P, Magallanes-Puebla A, Mancilla R. The mannose receptor is involved in the phagocytosis of mycobacteria-induced apoptotic cells. *J Immunol Res.* 2016;
62. Ganguli G, Mukherjee U, Sonawane A. Peroxisomes and oxidative stress: Their implications in the modulation of cellular immunity during mycobacterial infection. *Frontiers in Microbiology.* 2019.
63. Mehta M, Rajmani RS, Singh A. *Mycobacterium tuberculosis WhiB3* Responds to vacuolar pH-induced changes in mycothiol redox potential to modulate phagosomal maturation and virulence. *J Biol Chem.* 2016;
64. Sharp JD, Singh AK, Park ST, Lyubetskaya A, Peterson MW, Gomes ALC, et al. Comprehensive definition of the *SigH* regulon of *mycobacterium tuberculosis* reveals transcriptional control of diverse stress responses. *PLoS One.* 2016;
65. Espert L, Beaumelle B, Vergne I. Autophagy in *Mycobacterium tuberculosis* and HIV infections. *Front Cell Infect Microbiol.* 2015;
66. Lam A, Prabhu R, Gross CM, Riesenber LA, Singh V, Aggarwal S. Role of apoptosis and autophagy in tuberculosis. *American Journal of Physiology - Lung Cellular and Molecular Physiology.* 2017.
67. Venketaraman V. Understanding the host immune response against *Mycobacterium tuberculosis* infection. *Underst Host Immune Response Against Mycobacterium Tuberc Infect.* 2018;1–144.
68. Domingo-Gonzalez R, Prince O, Cooper A, Khader SA. Cytokines and Chemokines in *Mycobacterium tuberculosis* Infection. *Microbiol Spectr.* 2016;
69. Wong KW, Jacobs WR. Postprimary tuberculosis and macrophage necrosis: Is there a big conNECtion? *MBio.* 2016;
70. Dheeda Keertan, Schwander Stephan, and Zhu Bingdong JWM.2010.The Immunology of Tuberculosis: from bench to bedside, 15(2):294-309
71. Hunter RL. Tuberculosis as a three-act play: A new paradigm for the pathogenesis of pulmonary tuberculosis. *Tuberculosis.* 2016;

72. Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Pengendalian Tuberkulosis 2016. Kementerian Kesehatan Republik Indonesia. 2016. 163 p.
73. Loddenkemper R, Lipman M, Zumla A. Clinical aspects of adult tuberculosis. *Cold Spring Harb Perspect Med*. 2016;
74. Basem Abbas AI U. The Radiological Diagnosis of Pulmonary Tuberculosis (TB) in Primary Care. *J Fam Med Dis Prev*. 2018;
75. Zumla AI, Gillespie SH, Hoelscher M, Philips PPJ, Cole ST, Abubakar I, et al. New antituberculosis drugs, regimens, and adjunct therapies: Needs, advances, and future prospects. *The Lancet Infectious Diseases*. 2014.
76. Ramadhan S, Subroto YW, Probandari A. Identifikasi Faktor yang Mempengaruhi Keberhasilan Pengobatan Penderita Tuberkulosis di Kabupaten Bima 20142016. *Media Penelitian dan Pengembangan Kesehatan*. 2019;
77. Kriel M, Lotz JW, Kidd M, Walzl G. Evaluation of a radiological severity score to predict treatment outcome in adults with pulmonary tuberculosis. *Int J Tuberc Lung Dis*. 2015;
78. Rockwood N, du Bruyn E, Morris T, Wilkinson RJ. Assessment of treatment response in tuberculosis. *Expert Review of Respiratory Medicine*. 2016.
79. Luo Y, Zheng SG. Hall of fame among pro-inflammatory cytokines: Interleukin-6 gene and its transcriptional regulation mechanisms. *Frontiers in Immunology*. 2016.
80. Schett G. Physiological effects of modulating the interleukin-6 axis. *Rheumatol (United Kingdom)*. 2018;
81. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, Immunity, And disease. *Cold Spring Harb Perspect Biol*. 2014;
82. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: Designing specific therapeutics for a complex cytokine. *Nature Reviews Drug Discovery*. 2018.
83. Singh PP. Interleukin-6: a potential biomarker of the success of tuberculosis treatment. *Int J Infect Dis*. 2016;
84. Dotulong JFJ, Sapulete MR, Kandou GD. Hubungan faktor risiko umur, jenis kelamin dan kepadatan hunian dengan kejadian penyakit TB paru di desa wori kecamatan wori.2015;9.
85. Dowdy DW, Basu S, Andrews JR. Is Passive Diagnosis Enough? 2013;187:9.
86. Lim DSS. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–

- 2010: a systematic analysis for the Global Burden of Disease Study 2010. 2012;380:37
87. Muchtar NH, Herman D. Gambaran Faktor Risiko Timbulnya Tuberkulosis Paru pada Pasien yang Berkunjung ke Unit DOTS RSUP Dr. M. Djamil Padang Tahun 2015. :8
88. Horton KC, MacPherson P. Sex Differences in Tuberculosis Burden and Notifications in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. *PLOS Med.* 2016;23.
89. Geleta DA. Xpert MTB/RIF assay for diagnosis of pulmonary tuberculosis in sputum specimens in remote health care facility. 2015;6.
90. Triawanti, Fakhrurrozi M, Waspada C. Perubahan Indeks Massa Tubuh Penderita Tuberkulosis Paru Setelah Mendapat Obat Antituberkulosis Fase Intensif. 2005;
91. Chaudhry LA, Al-Shamri AS, Ba Essa EM. The rates of sputum conversion among new smear positive open pulmonary tuberculosis patients treated under directly observed treatment, short course strategy. *Saudi Med J.* 2014 Jan;35(1):39–43
92. Kartikasari W, Putra ON, Hardiyono H, Faizah AK. Korelasi antara konversi BTA pada fase intensif dan lanjutan pada pasien TB paru kategori I. 2021;8.
93. Nurul A, H. Pranggono E, Andriyoko B. Gambaran Konversi Sputum Bakteri Tahan Asam (BTA) dan Vitamin D Pada Penderita Tuberkulosis Paru Kasus Baru. *Indones J CHEST Crit Emerg Med.* Maret 2016;3(1).
94. Rabahi MF, Silva Júnior JLR da, Ferreira ACG, Tannus-Silva DGS, Conde MB. Tuberculosis treatment. *J Bras Pneumol.* Desember 2017;43(6):472–86.
95. Joshi L, Ponnana M, Sivangala R, Chelluri LK, Nallari P, Penmetsa S, dkk. Evaluation of TNF- α , IL-10 and IL-6 Cytokine Production and Their Correlation with Genotype Variants amongst Tuberculosis Patients and Their Household Contacts. *PLoS ONE.* 11 September 2015;10(9):e0137727.
96. Shu C-C, Wu M-F, Hsu C-L, Huang C-T, Wang J-Y, Hsieh S-L, dkk. Apoptosis-associated biomarkers in tuberculosis: promising for diagnosis and prognosis prediction. *BMC Infect Dis.* 28 Januari 2013;13:45.
97. Djoba Siaway JF, Beyers N, van Helden P, Walzl G. Differential cytokine secretion and early treatment response in patients with pulmonary tuberculosis. *Clin Exp Immunol.* April 2009;156(1):69–77.
98. Rockwood N, du Bruyn E, Morris T, Wilkinson RJ. Assessment of treatment response in tuberculosis. *Expert Rev Respir Med.* Juni 2016;10(6):643–54.

99. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. *Cold Spring Harb Perspect Biol.* Oktober 2014;6(10):6295.
100. Schett G. Physiological effects of modulating the interleukin-6 axis. *Rheumatol Oxf Engl.* 1 Februari 2018;57(suppl_2):ii43–50.
101. Luo Y, Zheng SG. Hall of Fame among Pro-inflammatory Cytokines: Interleukin-6 Gene and Its Transcriptional Regulation Mechanisms. *Front Immunol.* 2016;7:604.

LAMPIRAN 1.**A. PROSEDUR KERJA**

1. Siapkan semua reagen dan larutan standar yang akan digunakan.
2. Lepaskan kelebihan strip microplate dari bingkainya, letakkan kembali dalam kantong foil yang berisi paket pengering dan tutup rapat.
3. Tambahkan 100 µL Diluent RD1W ke masing-masing sumur / well.
4. Tambahkan 100 µL standar, kontrol, atau sampel per sumur. Tutup dengan strip perekat yang disediakan. Diinkubasi selama 2 jam di suhu kamar pada shaker microplate orbital horizontal (0,12 "orbit) diatur pada $500 \pm 50\text{rpm}$.
5. Sedot setiap sumur dan cuci, ulangi proses ini tiga kali dengan total empat kali pencucian. Cuci dengan mengisi setiap sumur dengan Wash Buffer (400 µL) menggunakan botol semprot, dispenser, atau autowasher. Setelah pencucian terakhir, singkirkan sisa pencuci / wash buffer dengan disedot. Balikkan plate dan bersihkan dengan handuk kertas bersih.
6. Tambahkan 200 µL Human IL-6 HS Conjugate ke masing-masing sumur. Tutup dengan strip perekat baru. Inkubasi selama 1 jam di suhu kamar pada shaker.
7. Ulangi pencucian seperti pada langkah 5.
8. Tambahkan 200 µL Streptavidin Polymer-HRP (1X) ke masing-masing sumur. Tutup dengan strip perekat baru. Inkubasi selama 30 menit di suhu kamar pada shaker.
9. Ulangi pencucian seperti pada langkah 5.
10. Tambahkan 200 µL Substrate Solution ke setiap sumur. Diinkubasi selama 30 menit pada suhu kamar di atas meja. Lindungi dari

cahaya.

11. Tambahkan 50 μL dari Stop Solution ke masing-masing sumur. Warna disumur harus berubah dari biru menjadi kuning. Jika warna dalam sumur berwarna hijau atau perubahan warna tidak tampak seragam, ketuk piring dengan lembut untuk memastikan pencampuran yang menyeluruh / homogen.
12. Tentukan optical density masing-masing sumur dalam waktu 30 menit, menggunakan microplate reader atur ke 450 nm. Jika koreksi panjang gelombang tersedia, atur ke 540 nm atau 570 nm. Jika koreksi panjang gelombang tidak tersedia, kurangi bacaan pada 540 nm atau 570 nm dari bacaan di 450 nm. Pengurangan ini akan mengoreksi ketidaksempurnaan optik di plate. Bacaan dilakukan langsung pada 450 nm tanpa koreksi mungkin lebih tinggi dan kurang akurat.

B. REAGEN

1. Wash Buffer
2. Substrate Solution
3. Streptavidin Polymer-HRP (1X)
4. Human IL-6 HS Standard

LAMPIRAN 2.

KEMENTERIAN PENDIDIKAN, KEBUDAYAAN, RISET DAN TEKNOLOGI

UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN

KOMITE ETIK PENELITIAN KESEHATAN

RSPTN UNIVERSITAS HASANUDDIN

RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR

Sekretariat : Lantai 2 Gedung Laboratorium Terpadu

JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.

Contact Person: dr. Agussalim Bukhari.,MMed.,PhD, Sp.GK TELP. 081241850858, 0411 5780103, Fax : 0411-581431



REKOMENDASI PERSETUJUAN ETIK

Nomor : 635/UN4.6.4.5.31 / PP36/ 2021

Tanggal: 29 September 2021

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH21090608	No Sponsor Protokol	
Peneliti Utama	dr. Dicky Wahyudi	Sponsor	
Judul Peneliti	Hubungan kadar Interleukin 6 dengan konversi sputum pada pengobatan tuberkulosis paru		
No Versi Protokol	1	Tanggal Versi	4 Oktober 2021
No Versi PSP		Tanggal Versi	
Tempat Penelitian	RS Dr. Wahidin Sudirohusodo dan RS Labuang Baji Makassar		
Jenis Review	<input checked="" type="checkbox"/> Exempted <input type="checkbox"/> Expedited <input type="checkbox"/> Fullboard Tanggal	Masa Berlaku 29 September 2021 sampai 29 September 2022	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)	 Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)	Tanda tangan	

Kewajiban Peneliti Utama:

- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 Jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari protokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

LAMPIRAN 3

Tabel 1. Karakteristik Sampel Penelitian
Frequencies

Statistics		Umur
N	Valid	51
	Missing	0
Mean		35.8824
Std. Deviation		14.11191
Range		49.00
Minimum		18.00
Maximum		67.00

Frequency Table

umur_2					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	18-39	34	66.7	66.7	66.7
	40-59	14	27.5	27.5	94.1
	>60	3	5.9	5.9	100.0
	Total	51	100.0	100.0	

JK					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	laki-laki	30	58.8	58.8	58.8
	perempuan	21	41.2	41.2	100.0
	Total	51	100.0	100.0	

TCM					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	very low	2	3.9	3.9	3.9
	low	27	52.9	52.9	56.9
	medium	18	35.3	35.3	92.2
	high	4	7.8	7.8	100.0
	Total	51	100.0	100.0	

IMTc1					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	underweight	24	47.1	47.1	47.1
	normal	24	47.1	47.1	94.1
	overweight	3	5.9	5.9	100.0
	Total	51	100.0	100.0	

BTAX					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	Tidak Konversi	13	25.5	25.5	25.5

Konversi	38	74.5	74.5	100.0
Total	51	100.0	100.0	

incr_BB					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	meningkat	36	70.6	70.6	70.6
	tidak meningkat	15	29.4	29.4	100.0
	Total	51	100.0	100.0	

IMTc2					
	Frequency	Percent	Valid Percent	Cumulative Percent	
Valid	underweight	19	37.3	37.3	37.3
	normal	25	49.0	49.0	86.3
	overweight	4	7.8	7.8	94.1
	obese1	3	5.9	5.9	100.0
	Total	51	100.0	100.0	

Tabel 2. Karakteristik Pemeriksaan Penunjang Crosstabs

BTA_1 * BTA_2 Crosstabulation

BTA_1	BTA_2	BTA_2			Total
		Konversi	tidak Konversi		
BTA_1	1.00	Count	27	2	29
		% within BTA_2	71.1%	15.4%	56.9%
	2.00	Count	10	5	15
		% within BTA_2	26.3%	38.5%	29.4%
	3.00	Count	1	6	7
		% within BTA_2	2.6%	46.2%	13.7%
Total		Count	38	13	51
		% within BTA_2	100.0%	100.0%	100.0%

Crosstabs

Foto1 * Foto2 Crosstabulation

Foto1	Foto2	Foto2			Total
		Lesi Minimal	Lesi Sedang	Lesi Luas	
Foto1	Lesi Minimal	Count	15	0	0
		% within Foto2	57.7%	0.0%	0.0%
	Lesi Sedang	Count	11	9	0
		% within Foto2	42.3%	37.5%	0.0%
	Lesi Luas	Count	0	15	1
		% within Foto2	0.0%	62.5%	100.0%
Total		Count	26	24	1
		% within Foto2	100.0%	100.0%	100.0%

NPar Tests**Marginal Homogeneity Test**

	BTA_1 & BTA_2	Rad 1 & Rad 2
Distinct Values	4	3
Off-Diagonal Cases	49	26
Observed MH Statistic	78.000	67.000
Mean MH Statistic	44.500	54.000
Std. Deviation of MH Statistic	5.123	2.550
Std. MH Statistic	6.539	5.099
Asymp. Sig. (2-tailed)	.000	.000

Tabel 3. Karakteristik IL-6**Statistics**

IL61		
N	Valid	51
	Missing	0
Mean		16.7360
Median		10.8700
Std. Deviation		16.59546
Variance		275.409
Minimum		1.14
Maximum		65.58

Frequency Table

		IL6_prod			
		Frequency	Percent	Valid Percent	Cumulative Percent
Valid	<10	25	49.0	49.0	49.0
	>10	26	51.0	51.0	100.0
	Total	51	100.0	100.0	

Tabel 4. Kadar IL-6 terhadap tingkat kepositifan Sputum BTA.
Correlations

Spearman's rho	IL61	IL61		BTA_1
		Correlation Coefficient		1.000
		Sig. (2-tailed)	N	.426**
	BTA_1	.	51	.002
		Correlation Coefficient	.	51
		Sig. (2-tailed)	51	.

Tabel 5. Perbandingan kadar IL-6 terhadap Konversi Sputum BTA
BTA_2**Descriptives**

BTA_2		Statistic	Std. Error
IL61	Konversi	Mean	10.2079
		95% Confidence Interval for	1.95006
		Lower Bound	6.2568

	Mean	Upper Bound	14.1591	
	5% Trimmed Mean		8.4749	
	Median		6.8900	
	Variance		144.504	
	Std. Deviation		12.02096	
	Minimum		1.14	
	Maximum		65.58	
	Range		64.44	
	Interquartile Range		9.50	
	Skewness		3.094	.383
	Kurtosis		12.003	.750
tidak Konversi	Mean		35.8181	3.64340
	95% Confidence Interval for Mean	Lower Bound	27.8798	
		Upper Bound	43.7564	
	5% Trimmed Mean		35.5524	
	Median		33.1220	
	Variance		172.567	
	Std. Deviation		13.13648	
	Minimum		15.54	
	Maximum		60.88	
	Range		45.34	
	Interquartile Range		13.85	
	Skewness		.701	.616
	Kurtosis		.330	1.191

BTA_2	Tests of Normality			Shapiro-Wilk		
	Statistic	df	Sig.	Statistic	df	Sig.
IL61 Konversi	.225	38	.000	.667	38	.000
tidak Konversi	.173	13	.200*	.932	13	.365

Mann-Whitney Test

Test Statistics^a

IL61	
Mann-Whitney U	29.000
Wilcoxon W	770.000
Z	-4.712
Asymp. Sig. (2-tailed)	

Tabel 6. Nilai Cut-off, AUC, Sensitifitas dan Spesifisitas IL-6 ROC curve

Variable	il6
Classification variable	bta
Sample size	51
Positive group ^a	13 (25.49%)

Negative group ^b	38 (74.51%)
^a bta = 1	
^b bta = 0	
Disease prevalence (%)	25.5
Area under the ROC curve (AUC)	
Area under the ROC curve (AUC)	0.941
Standard Error ^a	0.0329
95% Confidence interval ^b	0.838 to 0.988
z statistic	13.425
Significance level P (Area=0.5)	<0.0001

^a DeLong et al., 1988^b Binomial exact**Optimal criterion**

Optimal criterion ^a	>16.21
Sensitivity	92.31
Specificity	89.47

^a Taking into account disease prevalence (25.5%) and estimated costs:


cost False Positive: 1; cost False Negative: 1

cost True Positive: 0; cost True Negative: 0

Criterion values and coordinates of the ROC curve [Hide]

Criterion	Sensitivity	95% CI	Specificity	95% CI	+LR	95% CI	-LR	95% CI	+PV	95% CI	-PV	95% CI	Cost
≥1.14	100.00	75.3 - 100.0	0.00	0.0 - 9.3	1.00	1.0 - 1.0			25.5	25.5 - 25.5			0.745
>1.14	100.00	75.3 - 100.0	2.63	0.07 - 13.8	1.03	1.0 - 1.1	0.00		26.0	25.0 - 25.0	100.0		0.725
>1.18	100.00	75.3 - 100.0	5.26	0.6 - 17.7	1.06	1.0 - 1.1	0.00		26.5	25.1 - 25.1	100.0		0.706
>1.36	100.00	75.3 - 100.0	10.53	2.9 - 24.8	1.12	1.0 - 1.1	0.00		27.7	25.5 - 25.5	100.0		0.667
>1.75	100.00	75.3 - 100.0	13.16	4.4 - 28.1	1.15	1.0 - 1.3	0.00		28.3	25.8 - 25.8	100.0		0.647
>1.84	100.00	75.3 - 100.0	15.79	6.0 - 31.3	1.19	1.0 - 1.4	0.00		28.9	26.1 - 26.1	100.0		0.627
>1.96	100.00	75.3 - 100.0	18.42	7.7 - 34.3	1.23	1.1 - 1.4	0.00		29.5	26.5 - 26.5	100.0		0.608
>2.2	100.00	75.3 - 100.0	21.05	9.6 - 37.3	1.27	1.1 - 1.5	0.00		30.2	26.9 - 26.9	100.0		0.588
>2.86	100.00	75.3 - 100.0	23.68	11.4 - 40.2	1.31	1.1 - 1.6	0.00		31.0	27.3 - 27.3	100.0		0.569
>3.11	100.00	75.3 - 100.0	26.32	13.4 - 43.1	1.36	1.1 - 1.6	0.00		31.7	27.7 - 27.7	100.0		0.549
>3.46	100.00	75.3 - 100.0	28.95	15.4 - 45.9	1.41	1.1 - 1.7	0.00		32.5	28.2 - 28.2	100.0		0.529
>3.5	100.00	75.3 - 100.0	31.58	17.5 - 48.7	1.46	1.2 - 1.8	0.00		33.3	28.7 - 28.7	100.0		0.510
>3.76	100.00	75.3 - 100.0	34.21	19.6 - 51.4	1.52	1.2 - 1.9	0.00		34.2	29.3 - 29.3	100.0		0.490
>4.02	100.00	75.3 - 100.0	36.84	21.8 - 54.0	1.58	1.2 - 2.0	0.00		35.1	29.8 - 29.8	100.0		0.471
>4.97	100.00	75.3 - 100.0	39.47	24.0 - 56.6	1.65	1.3 - 2.1	0.00		36.1	30.4 - 30.4	100.0		0.451
>5.5	100.00	75.3 - 100.0	42.11	26.3 - 59.2	1.73	1.3 - 2.3	0.00		37.1	31.1 - 31.1	100.0		0.431
>6.56	100.00	75.3 - 100.0	44.74	28.6 - 61.7	1.81	1.4 - 2.4	0.00		38.2	31.7 - 31.7	100.0		0.412
>6.58	100.00	75.3 - 100.0	47.37	31.0 - 64.2	1.90	1.4 - 2.6	0.00		39.4	32.5 - 32.5	100.0		0.392
>6.67	100.00	75.3 - 100.0	50.00	33.4 - 66.6	2.00	1.5 - 2.7	0.00		40.6	33.2 - 33.2	100.0		0.373
>7.11	100.00	75.3 - 100.0	52.63	35.8 - 69.1	2.11	1.5 - 3.0	0.00		41.9	34.1 - 34.1	100.0		0.353
>7.75	100.00	75.3 - 100.0	55.26	38.3 - 71.4	2.24	1.6 - 3.2	0.00		43.3	34.9 - 34.9	100.0		0.333

>8.34	100.00	75.3 - 10 0.0	57.89	40.8 - 73 .7	2.3 7	1.6 - 3. 4	0.0 0		44. 8	35.9 - 5 4.1	100 .0		0.31 4	
>8.36	100.00	75.3 - 10 0.0	60.53	43.4 - 76 .0	2.5 3	1.7 - 3. 8	0.0 0		46. 4	36.9 - 5 6.2	100 .0		0.29 4	
>9.85	100.00	75.3 - 10 0.0	63.16	46.0 - 78 .2	2.7 1	1.8 - 4. 1	0.0 0		48. 1	38.0 - 5 8.5	100 .0		0.27 5	
>9.96	100.00	75.3 - 10 0.0	65.79	48.6 - 80 .4	2.9 2	1.9 - 4. 5	0.0 0		50. 0	39.2 - 6 0.8	100 .0		0.25 5	
>10.87	100.00	75.3 - 10 0.0	68.42	51.3 - 82 .5	3.1 7	2.0 - 5. 1	0.0 0		52. 0	40.4 - 6 3.4	100 .0		0.23 5	
>11.01	100.00	75.3 - 10 0.0	71.05	54.1 - 84 .6	3.4 5	2.1 - 5. 7	0.0 0		54. 2	41.8 - 6 6.0	100 .0		0.21 6	
>11.09	100.00	75.3 - 10 0.0	73.68	56.9 - 86 .6	3.8 0	2.2 - 6. 5	0.0 0		56. 5	43.3 - 6 8.9	100 .0		0.19 6	
>12.42	100.00	75.3 - 10 0.0	76.32	59.8 - 88 .6	4.2 2	2.4 - 7. 5	0.0 0		59. 1	44.9 - 7 1.9	100 .0		0.17 6	
>12.93	100.00	75.3 - 10 0.0	78.95	62.7 - 90 .4	4.7 5	2.6 - 8. 8	0.0 0		61. 9	46.7 - 7 5.0	100 .0		0.15 7	
>13.82	100.00	75.3 - 10 0.0	81.58	65.7 - 92 .3	5.4 3	2.8 - 10. 6	0.0 0		65. 0	48.7 - 7 8.4	100 .0		0.13 7	
>14.89	100.00	75.3 - 10 0.0	84.21	68.7 - 94 .0	6.3 3	3.0 - 13. 2	0.0 0		68. 4	51.0 - 8 1.9	100 .0		0.11 8	
>15.54	92.31	64.0 - 99 .8	84.21	68.7 - 94 .0	5.8 5	2.8 - 12. .4	0.0 91	0.01 - 0.6	66. 7	48.6 - 8 0.9	97. 0	82.9 - 9 9.5	0.13 7	
>15.56	92.31	64.0 - 99 .8	86.84	71.9 - 95 .6	7.0 2	3.1 - 16. .1	0.0 89	0.01 - 0.6	70. 6	51.1 - 8 4.6	97. 1	83.3 - 9 9.5	0.11 8	
>16.21	92.31	64.0 - 99 .8	89.47	75.2 - 97 .1	8.7 7	3.4 - 22. .5	0.0 86	0.01 - 0.6	75. 0	54.0 - 8 8.5	97. 1	83.8 - 9 9.6	0.09 80	
>21.09	84.62	54.6 - 98 .1	89.47	75.2 - 97 .1	8.0 4	3.1 - 20. .9	0.1 7	0.05 - 0.6	73. 3	51.4 - 8 7.7	94. 4	82.5 - 9 8.4	0.11 8	
>22.43	84.62	54.6 - 98 .1	92.11	78.6 - 98 .3	10. 72	3.5 - 32. .5	0.1 7	0.05 - 0.6	78. 6	54.7 - 9 1.8	94. 6	83.0 - 9 8.4	0.09 80	
>27.15	76.92	46.2 - 95 .0	92.11	78.6 - 98 .3	9.7 4	3.2 - 30. .0	0.2 5	0.09 - 0.7	76. 9	51.9 - 9 1.1	92. 1	81.2 - 9 6.9	0.11 8	
>28.75	69.23	38.6 - 90 .9	92.11	78.6 - 98 .3	8.7 7	2.8 - 27. .6	0.3 3	0.1 - 0. 8	75. 0	48.8 - 9 0.4	89. 7	79.4 - 9 5.2	0.13 7	
>29.69	61.54	31.6 - 86 .1	92.11	78.6 - 98 .3	7.7 9	2.4 - 25. .1	0.4 2	0.2 - 0. 8	72. 8	45.3 - 8 7	87. 5	77.8 - 9 3.3	0.15 7	
>32.3	61.54	31.6 - 86 .1	94.74	82.3 - 99 .4	11. 69	2.8 - 48. .2	0.4 1	0.2 - 0. 8	80. 0	49.3 - 9 4.3	87. 8	78.3 - 9 3.5	0.13 7	
>33.00	53.85	25.1 - 80 1	94.74	82.3 - 99 .4	10. 23	2.4 - 43. .2	0.4 9	0.3 - 0. 9	77. 8	45.3 - 9 3.7	85. 7	76.8 - 9 1.6	0.15 7	
>33.12	46.15	19.2 - 74 2	94.74	82.3 - 99 .4	8.7 7	2.0 - 38. .2	0.5 7	0.3 - 0. 9	75. 0	40.8 - 9 2.9	83. 7	75.6 - 8 9.5	0.17 6	
>33.64	46.15	19.2 - 74 1	97.37	86.2 - 99 .9	17. 54	2.3 - 13. 2.4	0.5 5	0.3 - 0. 9	85. 7	44.3 - 9 7.8	84. 1	76.1 - 8 9.8	0.15 7	
>33.91	38.46	13.9 - 68 9	97.37	86.2 - 99 .9	14. 62	1.9 - 11. 3.8	0.6 3	0.4 - 1. 0	83. 3	39.1 - 9 7.5	82. 2	75.0 - 8 7.7	0.17 6	
>39.74	30.77	9.1 - 61. 3	97.37	86.2 - 99 .9	11. 69	1.4 - 95. .4	0.7 1	0.5 - 1. 0	80. 0	32.9 - 9 7.0	80. 4	74.0 - 8 5.6	0.19 6	
>40.78	23.08	5.0 - 53. 8	97.37	86.2 - 99 .9	8.7 7	1.0 - 77. .1	0.7 9	0.6 - 1. 1	75. 0	25.4 - 9 6.3	78. 7	73.2 - 8 3.3	0.21 6	
>42.82	15.38	1.9 - 45. 4	97.37	86.2 - 99 .9	5.8 5	0.6 - 59. .3	0.8 7	0.7 - 1. 1	66. 7	16.5 - 9 5.3	77. 1	72.6 - 8 1.0	0.23 5	
>59.14	7.69	0.2 - 36. 0	97.37	86.2 - 99 .9	2.9 2	0.2 - 43. .5	0.9 5	0.8 - 1. 1	50. 0	6.3 - 93 .7	75. 5	72.3 - 7 8.4	0.25 5	
>60.87	0.00	0.0 - 24. 7	97.37	86.2 - 99 .9	0.0 0			1.0 3	1.0 - 1. 1	0.0 0		74. 0	73.0 - 7 5.0	0.27 5
>65.58	0.00	0.0 - 24. 7	100.00	90.7 - 10 0.0				1.0 0	1.0 - 1. 0			74. 5	74.5 - 7 4.5	0.25 5



Tabel 6. Hubungan Antara kadar IL-6 dengan Konversi Sputum BTA pada pasien TB.

Crosstabs

IL6X * BTAX Crosstabulation

IL6X	<16.21	BTAX		Total	
		Konversi	tidak Konversi		
	<16.21	Count	34	35	
		% within BTAX	89.5%	68.6%	
	>16.21	Count	4	16	
		% within BTAX	10.5%	31.4%	
Total		Count	38	51	
		% within BTAX	100.0%	100.0%	

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	30.090 ^a	1	.000		
Continuity Correction ^b	26.411	1	.000		
Likelihood Ratio	30.824	1	.000		
Fisher's Exact Test				.000	.000
Linear-by-Linear Association	29.500	1	.000		
N of Valid Cases	51				

- a. 1 cells (25.0%) have expected count less than 5. The minimum expected count is 4.08.
 b. Computed only for a 2x2 table

Risk Estimate		95% Confidence Interval	
	Value	Lower	Upper
Odds Ratio for IL6X (<16.21 / >16.21)	102.000	10.350	1005.228
For cohort BTAX = Konversi	3.886	1.660	9.097
For cohort BTAX = tidak Konversi	.038	.005	.268
N of Valid Cases	51		

LAMPIRAN 4
MASTER TABEL

No	Mr	Pasien	Umur	Pendidikan	JK	Alamat	Keluhan Pre Terapi	Keluhan Post Terapi	Berat Badan Pre Terapi	Berat Badan Post Terapi 2 Bln
1	146055	Murni	37	SMA	2	BT Ramba	Batuk berdahak, Sesak napas	Batuk berdahak	40	44
2	362814	Dg. Baji	63	SD	2	Kec. Mamajang	Batuk berdahak, Sesak napas	Batuk berdahak	30	32
3	366451	Agustina Lopak	50	SMP	2	Rapocini	Batuk berdahak, Sesak napas, Nyeri dada	Batuk berdahak	43	48
4	367739	Triyani Kartika	25	SMP	2	Jeneponto	Nyeri dada	Nyeri dada	48	50
5	369932	Syamsiah	56	SMP	2	Makassar	Batuk darah, Sesak napas	Sesak napas	48	54
6	370723	Muh. Kafrawi L	27	SMA	1	Gowa	Batuk berdahak, Nyeri dada	Batuk berdahak	49	53
7	368685	Hasniati	34	SMA	2	Makassar	Batuk berdahak	Batuk berdahak	48	52
8	371511	Sundari	50	SMA	2	Makassar	Batuk berdahak	Batuk berdahak	53	60
9	371571	Suriyani	59	SMP	2	Makassar	Batuk darah, Sesak napas	Batuk darah, Sesak napas	48	48
10	367047	Maryani	48	SMP	2	Makassar	Sesak napas	Tidak ada keluhan	37	39
11	371598	Irfan	27	SMA	1	Bone	Batuk darah	Tidak ada keluhan	58	63
12	372272	Purwanto	28	SMP	1	Takalar	Batuk berdahak	Batuk berdahak	47	47
13	368920	Rusdi	43	SMA	1	Makassar	Sesak napas	Tidak ada keluhan	53	53
14	341514	Fajar Adillah	18	SMA	1	Makassar	Sesak napas	Sesak napas	41	41
15	368900	Lie Liwang	54	SMP	1	Makassar	Nyeri dada	Tidak ada keluhan	58	60
16	372939	Andas	23	SMA	1	Makassar	Batuk berdahak	Batuk berdahak	32	32
17	370009	Sutrisno	27	SMP	1	Takalar	Batuk darah	Tidak ada keluhan	47	54
18	373115	Dedi	24	SMA	1	Jeneponto	Batuk berdahak, Sesak napas	Sesak napas	40	43
19	373304	Agus	21	S1	1	Makassar	Batuk berdahak, Sesak napas	Batuk berdahak, Sesak napas	38	38
20	179745	Ridwan Hasan	35	SMA	1	Makassar	Batuk darah	Tidak ada keluhan	38	43

21	373577	Sanawiya	51	SMP	2	Makassar	Batuk berdahak, Sesak napas	Batuk berdahak	33	36
22	366427	Intan abd azis	39	S1	2	Makassar	Batuk berdahak, Sesak napas	Batuk berdahak, Sesak napas	38	38
23	364454	Muh Farhan	18	SMP	1	Makassar	Batuk berdahak	Batuk berdahak	70	75
24	373533	Muh Ansar Basri	20	SMA	1	Gowa	Batuk darah	Batuk berdahak	44	46
25	371598	Faisal M Asis Hakim	36	SMA	1	Manado	Batuk darah	Batuk berdahak	49	50
26	205921	Ilda Gunawan	48	SMP	2	Makassar	Batuk berdahak, Sesak napas	Sesak napas	49	55
27	280640	Andi Muh Faisal	27	SMA	1	Makassar	Batuk berdahak, Sesak napas	Batuk berdahak	55	60
28	374290	Abd kadir	32	SMP	1	Maros	Batuk berdahak	Tidak ada keluhan	44	50
29	374542	Priwantoro	26	SMA	1	Gowa	Batuk kering	Tidak ada keluhan	60	62
30	238170	Mariama	63	SMP	2	Makassar	Batuk berdahak, Sesak napas	Tidak ada keluhan	60	66
31	372800	Ervani Meilani Putri	19	SMA	2	Bulukumba	Batuk darah	Batuk darah	45	45
32	374134	Tho King Hwa	67	SMP	2	Makassar	Batuk berdahak	Tidak ada keluhan	38	42
33	375214	Amran	25	SMP	1	Bulukumba	Batuk kering	Tidak ada keluhan	50	54
34	374392	Defita Suciati	30	SMP	2	Pangkep	Batuk kering	Tidak ada keluhan	46	52
35	369865	Agnes Viona Kibo Tukan	21	S1	2	Nunukan	Batuk darah	Tidak ada keluhan	47	48
36	374956	Ronald	32	SMP	1	Makassar	Batuk darah	Batuk darah	56	56
37	374206	Syamsiar	52	SMP	2	Gowa	Sesak napas	Tidak ada keluhan	40	44
38	370742	Ahmad	25	SMA	1	Makassar	Sesak napas, Batuk berdahak	Batuk berdahak	42	44
39	375721	Agustinus	27	SMP	1	Sidrap	Sesak napas, Batuk berdahak	Sesak napas, Batuk berdahak	43	43
40	371743	Maning Dg Naba	50	SMP	1	Gowa	Sesak napas	Tidak ada keluhan	43	45
41	375538	Muh Fadil	22	SMA	1	Makassar	Batuk darah, Sesak napas	Batuk berdahak	50	54
42	375753	Mansyur	53	SMP	1	Pinrang	Sesak napas	Sesak napas	50	50
43	256276	Bebi yehezkiel	26	SMP	2	Makassar	Batuk berdahak	Tidak ada keluhan	42	46
44	375652	Abd Moekti	30	SMA	1	Makassar	Batuk berdahak	Tidak ada keluhan	38	42
45	375695	Halima	53	SMP	2	Makassar	Sesak napas	Sesak napas	38	38
46	370441	Ratna Sasmita	22	SMP	2	Bulukumba	Batuk darah	Tidak ada keluhan	45	45

47	371891	Denny Harlan D	21	SMP	1	Makassar	Batuk darah	Tidak ada keluhan	44	50
48	373650	Safri	39	SMP	1	Makassar	Batuk darah	Tidak ada keluhan	58	60
49	372692	Hasruddin S	28	SMP	1	Takalar	Sesak napas, Batuk berdahak	Sesak napas, Batuk berdahak	44	44
50	373315	Muh Jafar	55	SMP	1	Gowa	Sesak napas, Batuk berdahak	Sesak napas, Batuk berdahak	48	48
51	370595	Sufrenol	24	SMP	1	Takalar	Sesak napas	Tidak ada keluhan	47	50

Tinggi Badan	Tinggi Badan Post Terapi 2 Bln	IMT Pre Terapi	IMT Post Terapi 2 Bln	IL 6 pre	TCM	BTA		Foto Toraks Pre Terapi	Foto Toraks Post Terapi	HB Pre Terapi	Hb Post Terapi
						pre	post				
150	150	17.77777778	19.55555556	10.87	MTB Detected medium / Rif Resistance not detected	1+/2+	Neg / Neg	Lesi Minimal	Lesi Minimal	10	10
150	150	13.33333333	14.22222222	8.34	MTB Detected medium / Rif Resistance not detected	2+/2+	Neg / Neg	Lesi Sedang	Lesi Minimal	9.5	10
150	150	19.11111111	21.33333333	1.96	MTB Detected low / Rif Resistance not detected	Neg / 1+	Neg / Neg	Lesi Minimal	Lesi Minimal	8.5	9
155	155	19.97918835	20.81165453	4.97	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Sedang	Lesi Minimal	9	9.3
150	150	21.33333333	24	22.43	MTB Detected low / Rif Resistance not detected	1+ / 2+	Neg / Neg	Lesi Minimal	Lesi Minimal	9	10
171	171	16.75729284	18.12523512	13.82	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Minimal	Lesi Minimal	9.6	9.8
154	154	20.23950076	21.92612582	11.01	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Sedang	Lesi Minimal	10	9.7
158	158	21.23057202	24.03460984	29.69	MTB Detected Medium / Rif Resistance not detected	3+ / 3+	1+/1+	Lesi Sedang	Lesi Sedang	10	10
150	150	21.33333333	21.33333333	1.75	MTB Detected medium / Rif Resistance not detected	2+ / 1+	Neg / Neg	Lesi Luas	Lesi Sedang	8.7	9.5
118	118	26.5728239	28.00919276	4.02	MTB Detected low / Rif Resistance not detected	1+ / 2+	Neg / Neg	Lesi Sedang	Lesi Sedang	10	10.7
168	168	20.54988662	22.32142857	27.15	MTB Detected High/ Rif Resistance not detected	3+ / 3+	1+/1+	Lesi Luas	Lesi Sedang	9.7	9.5
167	167	16.8525225	16.8525225	33.641	MTB Detected High/ Rif Resistance not detected	3+ / 3+	Neg / Neg	Lesi Sedang	Lesi Minimal	10.2	10.6
162	162	20.19509221	20.19509221	3.46	MTB Detected low / Rif Resistance not detected	Neg / 1+	Neg / Neg	Lesi Minimal	Lesi Minimal	9.7	10
158	158	16.42365006	16.42365006	3.5	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Luas	Lesi Sedang	10.3	10.7

170	170	20.06920415	20.76124567	6.56	MTB Detected low / Rif Resistance not detected	1+ / 2+	Neg / Neg	Lesi Minimal	Lesi Minimal	10.4	10
158	158	12.81845858	12.81845858	3.76	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Luas	Lesi Luas	9	8.8
168	168	16.65249433	19.13265306	40.78	MTB Detected medium / Rif Resistance not detected	2+ / 1+	1+/1+	Lesi Sedang	Lesi Sedang	10	10.1
156	156	16.4365549	17.66929652	8.36	MTB Detected medium / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Minimal	Lesi Minimal	11.6	11.5
163	163	14.30238248	14.30238248	33.001	MTB Detected medium / Rif Resistance not detected	2+ / 1+	1+/1+	Lesi Luas	Lesi Sedang	11.5	11
140	140	19.3877551	21.93877551	65.581	MTB Detected very low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Luas	Lesi Sedang	9.7	10.2
150	150	14.66666667	16	12.93	MTB Detected medium / Rif Resistance not detected	2+ / 2+	Neg / Neg	Lesi Minimal	Lesi Minimal	11.3	11.5
140	140	19.3877551	19.3877551	5.5	MTB Detected low / Rif Resistance not detected	Neg / 1+	Neg / Neg	Lesi Sedang	Lesi Sedang	10	9.8
166	166	25.40281608	27.21730295	59.143	MTB Detected medium / Rif Resistance not detected	2+ / 2+	1+/1+	Lesi Sedang	Lesi Minimal	9.5	9
168	168	15.58956916	16.29818594	9.85	MTB Detected low / Rif Resistance not detected	2+/2+	Neg / Neg	Lesi Minimal	Lesi Minimal	10.5	11
170	170	16.9550173	17.30103806	2.86	MTB Detected low / Rif Resistance not detected	2+ / 2+	Neg / Neg	Lesi Sedang	Lesi Sedang	11	10.6
150	150	21.77777778	24.44444444	33.919	MTB Detected low / Rif Resistance not detected	1+/1+	1+/1+	Lesi Sedang	Lesi Minimal	10.7	10
170	170	19.03114187	20.76124567	11.09	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Minimal	Lesi Minimal	11.2	11
165	165	16.16161616	18.36547291	32.3	MTB Detected medium / Rif Resistance not detected	Neg / 1+	Neg / Neg	Lesi Minimal	Lesi Minimal	12.3	12
171	171	20.51913409	21.20310523	9.96	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Sedang	Lesi Minimal	10.7	10.5
160	160	23.4375	25.78125	33.122	MTB Detected low / Rif Resistance not detected	1+/1+	1+/1+	Lesi Luas	Lesi Sedang	9.8	9.5
153	153	19.22337562	19.22337562	1.18	MTB Detected low / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Luas	Lesi Sedang	10	9.5
152	152	16.44736842	18.17867036	6.58	MTB Detected medium / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Sedang	Lesi Sedang	9.7	10.3
165	165	18.36547291	19.83471074	28.75	MTB Detected medium / Rif Resistance not detected	2+/2+	1+/1+	Lesi Sedang	Lesi Sedang	10.4	10.6
150	150	20.44444444	23.11111111	1.36	MTB Detected low / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Luas	Lesi Sedang	9.7	10
148	148	21.45726808	21.9138057	2.2	MTB Detected low / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Sedang	Lesi Minimal	10.5	10.5
168	168	19.84126984	19.84126984	1.36	MTB Detected low / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Luas	Lesi Sedang	9.7	10

162	162	15.24157903	16.76573693	15.54	MTB Detected medium / Rif Resistance not detected	2+/2+	1+/1+	Lesi Luas	Lesi Sedang	8.7	8.5
165	165	15.42699725	16.16161616	12.42	MTB Detected low / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Sedang	Lesi Minimal	11.4	11
178	178	13.57151875	13.57151875	7.11	MTB Detected low / Rif Resistance not detected	Neg / 1+	Neg / Neg	Lesi Luas	Lesi Sedang	9.8	10
145	145	20.45184304	21.40309156	15.56	MTB Detected low / Rif Resistance not detected	Neg / 1+	Neg / Neg	Lesi Sedang	Lesi Sedang	10.3	10.6
165	165	18.36547291	19.83471074	16.21	MTB Detected medium / Rif Resistance not detected	1+/1+	Neg / Neg	Lesi Sedang	Lesi Sedang	9.4	8.5
150	150	22.22222222	22.22222222	1.14	MTB Detected medium / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Luas	Lesi Sedang	8.7	9.8
150	150	18.66666667	20.44444444	6.67	MTB Detected low / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Sedang	Lesi Minimal	10.7	11
150	150	16.88888889	18.66666667	39.743	MTB Detected High/ Rif Resistance not detected	3+ / 3+	1+/1+	Lesi Minimal	Lesi Minimal	11	11.3
140	140	19.3877551	19.3877551	21.09	MTB Detected High/ Rif Resistance not detected	3+ / 3+	1+/1+	Lesi Sedang	Lesi Minimal	8.7	9.3
155	155	18.73048907	18.73048907	3.11	MTB Detected low / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Minimal	Lesi Minimal	11	11.2
166	166	15.9674844	18.14486863	60.878	MTB Detected medium / Rif Resistance not detected	3+ / 3+	1+/1+	Lesi Luas	Lesi Sedang	9.5	9.8
175	175	18.93877551	19.59183673	14.89	MTB Detected very low / Rif Resistance not detected	Neg / 1+	Neg / Neg	Lesi Minimal	Lesi Minimal	11.3	11.6
156	156	18.08021039	18.08021039	7.75	MTB Detected low / Rif Resistance not detected	1+ / Neg	Neg / Neg	Lesi Minimal	Lesi Minimal	12	11.8
162	162	18.28989483	18.28989483	1.84	MTB Detected medium / Rif Resistance not detected	1+ / 2+	Neg / Neg	Lesi Luas	Lesi Sedang	10	9.5
165	165	17.26354454	18.36547291	42.829	MTB Detected medium / Rif Resistance not detected	3+ / 2+	1+/1+	Lesi Luas	Lesi Sedang	9.3	10